ArticleInternational journal of molecular sciences2025
Deep Sequencing Analysis of Hepatitis C Virus Subtypes and Resistance-Associated Substitutions in Genotype 4 Patients Resistant to Direct-Acting Antiviral (DAA) Treatment in Egypt.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Egypt has the highest global prevalence of hepatitis C virus (HCV), with genotype 4 (G4) in over 94% of cases. Direct-acting antivirals (DAAs) yield sustained virologic response (SVR) rates above 95%. Second-generation DAAs are recommended for patients with virological failure, achieving over 90% eradication. This study aimed to classify and evaluate the pattern of HCV resistance-associated substitutions (RASs) in patients who failed DAA treatment in Egypt. A total of 1778 chronically infected HCV patients from Egypt's Nile Delta were enrolled (2016-2018). Among them, 37 relapsed, and high-quality serum samples from 22 patients were available, including 6 cases with pre- and post-treatment samples. Next-generation sequencing (NGS) was performed for HCV subtyping and RAS identification. Among the 22 analyzed cases, 21 (95.4%) were G4: 11 were classified as subtype G4a, seven G4o, and three G4m. One patient (4.5%) was identified as G1g. One case shifted from G4a pre- to G4o post-treatment, suggesting reinfection. The RAS pattern in rare G4 subtypes (G4m/G4o) differs from the G4a subtype. The combination of L28M/L30S mutations was detected in 8/11 G4a samples; in contrast, RASs in G4o were characterized by T30S or Y93C/H/N/S substitutions. Notably, some substitutions identified as RASs may represent fixed polymorphisms in regional viral populations, such as those in Egypt's Nile Delta. HCV subtypes significantly influence the RAS pattern, particularly within the NS5A region, after DAA-treatment failure. The RAS pattern differs among G4 subtypes, particularly in rare ones, predisposing patients to resistance and underscoring the importance of NGS in regional populations to optimize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.